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Brian Fox died suddenly on 28th March 1999 at the age of 69. He
leaves behind a quite remarkable legacy of contributions to cancer
research. Unusually, he also achieved international distinction in a
second scientific field, the study of lichens, as well as having a
myriad of other interests.
Brian was born in South Wales in 1929 and although he spent
most of his life in the north of England he remained a proud
Welshman. He graduated in Chemistry in 1950 from Durham
University and continued there to obtain his PhD in 1954. His
doctoral thesis was on the isolation and characterization of plant
extracts such as the alkaloids of the lupin. This interest in natural
history, combined with a love of chemistry, shaped the rest of his
career. After national service for 2 years in the Royal Signals
Regiment he took up a post in the Paterson Laboratories, at the
renowned Christie Hospital in Manchester, where he remained for
the rest of his career with the exception of a sabbatical year at Yale
University as a Cancer Research Campaign (CRC) Fellow. He
became head of the Department of Experimental Chemotherapy at
the Paterson Laboratories and was appointed to a Personal Chair in
the University of Manchester in 1980 and as Deputy Director of the
Paterson Institute for Cancer Research in 1984. He retired in 1993.
Brian Fox’s interest in chemotherapeutic agents arose out of his
early work with Harold Jackson on agents which could modulate
fertility. He was particularly interested in understanding the role of
geometrical shape in the activity of drugs. This was particularly
true of his studies on the interaction of allkane sulphonate drugs
with chromatin. These studies led ultimately to the introduction of
methylene dimethane sulphonate (MDMS) into clinical trials. In
his later career he became particularly interested in developing
drugs from natural sources. This research was facilitated by the
close relationship he built up with Professor Bob Pettit of Arizona
State University, and led to the introduction of a range of new
agents, including bryostatin I, into clinical trials under the spon-
sorship of the CRC. He also realized the potential of Chinese
Traditional Medicine as a source of new agents. With the help of
Chinese colleagues a number of novel structures were isolated and
are now being evaluated as potential anticancer agents.
Brian, together with Tom Connors, was the driving force behind
the CRC Phase I/II Clinical Trials Committee and he served as
operational secretary from 1980 to 1992. The underlying concept
was a system that would fast-track potential cancer chemothera-
peutic agents into clinical trials. The mechanism established by
this group has been internationally recognized and many other
countries have adopted similar systems. In the UK this Committee
has evolved into a sophisticated collaboration between cancer
research organizations and is now beginning to reap the benefits of
the foresight of Brian Fox and Tom Connors. His international
distinction was also recognized by his membership of the council
of the European Organisation for Research and Treatment of
Cancer (EORTC). He was Chairman of the EORTC Screening and
Pharmacology Group and its New Drug Development Group, and
also a member of the prestigious National Cancer Institute/
EORTC/CRC Joint Steering Committee.
For Brian, lichens were no trouble – he loved them. He was a
very active member of the British Lichen Society and served as
Vice President and President. Not only did the study of lichens
take him to the hills of Derbyshire and other wild and remote
regions which he greatly enjoyed, it also provided a basis for some
valuable work in monitoring environmental pollution for local
councils in the North of England. He served on the Advisory
Committee for the British Lichen Flora. His botanical interests led
to his election in 1960 as a Fellow of the Linnean Society, and in
1986 he became a Council Member. He was a familiar figure in the
herbariun of the University of Manchester Museum and he was, at
the time of his death, involved in preparing exhibits for the
Wellcome Science for Life Exhibition, which is shortly to transfer
to Manchester.
He was also the unofficial archivist for the Christie Hospital and
had amassed a large collection of artefacts, documents and
recorded conversations with many of the distinguished figures
who contributed to the development of cancer treatment and
cancer research. A booklet based on this material was published a
few years ago and he had completed many chapters of a much
larger work. This material remains a wonderful opportunity for
further study on the history of cancer research and treatment.
He was an accomplished pianist and an artist with a special
interest in portrait painting. Those who worked most closely to
him know that he could be a demanding task master. However, his
enthusiasm for all he did was infectious and a number of his
students and research fellows have themselves become inter-
nationally known figures in the field of cancer chemotherapy. His
scientific philosophy and integrity live on in the work of many
students and colleagues who thrived under his guidance.
Sadly his wife, Margaret, also a distinguished scientist whom he
met and worked with at the Paterson Institute, died quite suddenly
several years ago. He will be greatly missed by his sister Mary,
other relatives and his many friends and colleagues around the
world.
Truly, this was a remarkable and busy life; a life’s work well
done.
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